| Novartis Pharma Schweiz AG - Votrient 400 mg, Filmtabletten | | 60326 | | 02 | | Votrient 400 mg | | Filmtabletten | | L01XE11 | | Pazopanib | | 27.08.2010 | | |
| | Composition | | pazopanibum 400 mg ut pazopanibi hydrochloridum 433.4 mg, cellulosum microcristallinum, carboxymethylamylum natricum A, povidonum K 30, magnesii stearas, Überzug: hypromellosum, macrogolum 400, polysorbatum 80, E 171, pro compresso obducto corresp. natrium 1.8 mg. | | Packungsbestandteile | | Coated tablets | | | | | Active Agent | Dose |
|---|
| Pazopanibum | 400 mg |
| | BAG: Active Agent | Dose |
|---|
| Pazopanibum | 400 mg |
| | | | Inactive agents | Dose | additional_information |
|---|
| Carboxymethylamylum Natricum A | | | | Cellulosum Microcristallinum | | | | E 171 | | color. | | Hypromellosum | | Überzug | | Macrogol | 400 | | | Magnesii Stearas | | | | Polysorbatum 80 | | | | Povidonum K | 30 | | | Pro Compresso Obducto | | |
| |
| | Package number | Package Size | EFP | CP | Category | SL | Out of trade (MedRef) |
|---|
| 002 | 60 Tablet(s) | 3213.46 | 3511.25 | A | SL | Yes |
|
|
